Clinical Trial Update: Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009) [Phase 1]

View source ↗

Summary

Phase 1 study of dalotuzumab (MK-0646) in adults with solid tumors has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Dalotuzumab (dalotuzumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2017-06-15